# Mineralys Therapeutics (MLYS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/MLYS
## Company Profile
- Ticker: MLYS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 26.99 USD
- Market cap: 2380070213.85 USD
- Last updated: 2026-08-06
## Business Overview
### Aldosterone-Driven Disease
Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone.
### Lorundrostat
Lorundrostat is an oral, selective aldosterone-synthase inhibitor under FDA review as an add-on treatment for adults with uncontrolled or resistant hypertension.
### Registrational Evidence
The application is supported by five clinical studies, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. The Transform-HTN extension continues to collect longer-term safety and efficacy data.
## Why The Stock Is Moving

As of Aug 6, 2026, MLYS closed up 0.52% at $26.99. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA target action date for lorundrostat on December 22, 2026.
- Potential U.S. launch of lorundrostat following approval.

## Recent News
- 2026-08-04 12:00 EST — [Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-announce-second-quarter-2026-financial-results-and-hos-3e424d6c) — Source: Mineralys Therapeutics
- 2026-07-27 20:01 EST — [Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635--a1d96146) — Source: Mineralys Therapeutics
- 2026-06-14 14:00 EST — [Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-fai-35eaa6f1) — Source: Mineralys Therapeutics
- 2026-06-08 20:05 EST — [Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68) — Source: Mineralys Therapeutics
- 2026-06-08 11:00 EST — [Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endo-03fb3c48) — Source: Mineralys Therapeutics